

The Fritsma Factor

YOUR INTERACTIVE HEMOSTASIS RESOURCE

Cheat Sheet—September 2026

Welcome to our September 2026 [Fritsma Factor](#) Cheat Sheet. The Alabama Weather Network tells me that while southern North America is experiencing a blistering late summer heat wave, our “Global South” participants in Sydney, Buenos Aires, Rwanda, and Rio De Janeiro are enjoying moderate early spring weather. A glance at our [Event and Conference Calendar](#) tells us there are many hemostasis-related activities coming up this fall. First in line, perhaps, is [World Thrombosis Day, October 13](#), this year featuring thrombosis threats to women’s lives.

August 2026 QQ: Coagulation Control Proteins

Our August 2026 Quick Question was a quiz that asked, [“Which is NOT an endogenous coagulation control protein?”](#) We scored well, reflecting the knowledge base of our FF participants. The summary gives a glimpse of venous embolic disease (VTE)-associated coagulation control protein deficiencies and recently released “rebalancing therapy” approaches used to manage hemophilia A and B bleed rates. Rebalancing reduces levels of the control proteins antithrombin or tissue factor pathway inhibitor, and possibly protein C, currently in development.

September 2026 QQ; Poll

Our September 2026 Quick Question asks, [“In your facility, what anticoagulant \(AC\) is used for lupus anticoagulant \(LAC\) patients with venous thromboembolic disease \(VTE\)?”](#) AC therapy is indicated for VTE, including VTE and fetal loss associated with the presence of chronic LAC in the plasma. The commonly used anti-FXa direct oral anticoagulants (DOACs) are rivaroxaban (Xarelto®) and apixaban (Eliquis®). The only anti-FIIa (thrombin) DOAC is dabigatran (Pradaxa®). The vitamin K antagonist (VKA) warfarin is often used as it has long been found effective for LAC-associated VTE. ACs interfere with standard clot-based LAC profiles, limiting their usefulness or requiring special plasma treatment. To answer the poll, please choose the most often-used AC in your institution. We welcome comments about AC choices and the means available for treating plasma before performing the LAC profile. For additional information on LAC and the family of antiphospholipid antibodies, visit our educational module, [Antiphospholipid Antibodies and the Lupus Anticoagulant Profile](#).

Monthly Cheat Sheet “Push” Copy

If you would like a “push” copy of this monthly Cheat Sheet with links to our recent posts, please complete the application form on the right. Fritsma Factor is hosted by our family of hemostasis diagnostics providers, [Precision BioLogic](#), [Affinity Biologicals](#), and [George King Bio-Medical](#), and all our services are gratis.

George A. Fritsma MS, MLS

The Fritsma Factor, Your Interactive Hemostasis Resource

george@fritsmafactor.com; www.fritsmafactor.com